Vanguard Group Inc. Buys 4,247,002 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vanguard Group Inc. grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXFree Report) by 37.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,506,834 shares of the company’s stock after acquiring an additional 4,247,002 shares during the quarter. Vanguard Group Inc. owned about 0.07% of Recursion Pharmaceuticals worth $118,627,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Citigroup Inc. increased its holdings in shares of Recursion Pharmaceuticals by 165.3% during the third quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock valued at $3,599,000 after acquiring an additional 293,174 shares in the last quarter. American Century Companies Inc. increased its holdings in Recursion Pharmaceuticals by 741.3% in the 3rd quarter. American Century Companies Inc. now owns 85,925 shares of the company’s stock worth $657,000 after buying an additional 75,712 shares in the last quarter. Deutsche Bank AG increased its holdings in Recursion Pharmaceuticals by 15.4% in the 3rd quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock worth $457,000 after buying an additional 7,973 shares in the last quarter. Creative Planning bought a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $140,000. Finally, GTS Securities LLC bought a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $80,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Needham & Company LLC lifted their price objective on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. TD Cowen assumed coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating for the company. Finally, KeyCorp lifted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.75.

Get Our Latest Report on Recursion Pharmaceuticals

Insider Activity

In other news, insider Shafique Virani sold 18,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $10.93, for a total transaction of $196,740.00. Following the transaction, the insider now directly owns 136,748 shares of the company’s stock, valued at approximately $1,494,655.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $9.22, for a total transaction of $445,067.84. Following the transaction, the chief executive officer now directly owns 774,703 shares of the company’s stock, valued at approximately $7,142,761.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Shafique Virani sold 18,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $10.93, for a total value of $196,740.00. Following the sale, the insider now directly owns 136,748 shares in the company, valued at approximately $1,494,655.64. The disclosure for this sale can be found here. Insiders have sold a total of 373,701 shares of company stock valued at $4,069,001 in the last ninety days. Corporate insiders own 19.96% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $8.93 on Thursday. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -5.76 and a beta of 0.76. The stock’s 50-day simple moving average is $11.08 and its two-hundred day simple moving average is $9.07. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.54 and a 52-week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. The business had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

(Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXFree Report).

Institutional Ownership by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.